https://www.cnbc.com/2021/08/12/delta-variant-delays-venom-let-there-be-carnage-until-october.html?__source=sharebar|twitter&par=sharebar
Morgan Stanley Initiates Coverage On United Therapeutics with Overweight Rating, Announces Price Target of $288
Morgan Stanley analyst Terence Flynn initiates coverage on United Therapeutics (NASDAQ:UTHR) with a Overweight rating and announces Price Target of $288.